Logo image of PTIX

PROTAGENIC THERAPEUTICS INC (PTIX) Stock Fundamental Analysis

NASDAQ:PTIX - Nasdaq - US74365N2027 - Common Stock

0.401  -0.04 (-8.66%)

Premarket: 0.404 +0 (+0.75%)

Fundamental Rating

1

Taking everything into account, PTIX scores 1 out of 10 in our fundamental rating. PTIX was compared to 572 industry peers in the Biotechnology industry. The financial health of PTIX is average, but there are quite some concerns on its profitability. PTIX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PTIX had negative earnings in the past year.
PTIX had a negative operating cash flow in the past year.
In the past 5 years PTIX always reported negative net income.
In the past 5 years PTIX always reported negative operating cash flow.
PTIX Yearly Net Income VS EBIT VS OCF VS FCFPTIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1M -2M -3M -4M -5M

1.2 Ratios

With a Return On Assets value of -374.44%, PTIX is not doing good in the industry: 96.46% of the companies in the same industry are doing better.
PTIX has a worse Return On Equity (-785.49%) than 83.01% of its industry peers.
Industry RankSector Rank
ROA -374.44%
ROE -785.49%
ROIC N/A
ROA(3y)-67.04%
ROA(5y)-139.9%
ROE(3y)-77.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTIX Yearly ROA, ROE, ROICPTIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PTIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTIX Yearly Profit, Operating, Gross MarginsPTIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for PTIX has been increased compared to 1 year ago.
PTIX has more shares outstanding than it did 5 years ago.
PTIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PTIX Yearly Shares OutstandingPTIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
PTIX Yearly Total Debt VS Total AssetsPTIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -41.21, we must say that PTIX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -41.21, PTIX is not doing good in the industry: 93.63% of the companies in the same industry are doing better.
There is no outstanding debt for PTIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -41.21
ROIC/WACCN/A
WACCN/A
PTIX Yearly LT Debt VS Equity VS FCFPTIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M 6M 8M

2.3 Liquidity

PTIX has a Current Ratio of 1.80. This is a normal value and indicates that PTIX is financially healthy and should not expect problems in meeting its short term obligations.
PTIX has a worse Current ratio (1.80) than 78.94% of its industry peers.
PTIX has a Quick Ratio of 1.80. This is a normal value and indicates that PTIX is financially healthy and should not expect problems in meeting its short term obligations.
PTIX has a Quick ratio of 1.80. This is in the lower half of the industry: PTIX underperforms 77.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.8
Quick Ratio 1.8
PTIX Yearly Current Assets VS Current LiabilitesPTIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for PTIX have decreased strongly by -39.55% in the last year.
EPS 1Y (TTM)-39.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PTIX Yearly Revenue VS EstimatesPTIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
PTIX Yearly EPS VS EstimatesPTIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PTIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTIX Price Earnings VS Forward Price EarningsPTIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTIX Per share dataPTIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTIX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTAGENIC THERAPEUTICS INC

NASDAQ:PTIX (1/21/2025, 8:22:12 PM)

Premarket: 0.404 +0 (+0.75%)

0.401

-0.04 (-8.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-31 2025-03-31
Inst Owners8.95%
Inst Owner Change0%
Ins Owners20.65%
Ins Owner Change0%
Market Cap2.72M
Analysts82.86
Price TargetN/A
Short Float %3.01%
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.79
P/tB 3.79
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -374.44%
ROE -785.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.04%
ROA(5y)-139.9%
ROE(3y)-77.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.8
Quick Ratio 1.8
Altman-Z -41.21
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-108.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.56%
OCF growth 3YN/A
OCF growth 5YN/A